Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship

被引：37

作者：

Kato, Hideaki ^{[1
,2
]}

Shimizu, Hiroyuki ^{[3
]}

Shibue, Yasushi ^{[4
]}

Hosoda, Tomohiro ^{[5
]}

Iwabuchi, Keisuke ^{[6
]}

Nagamine, Kotaro ^{[7
]}

Saito, Hiroki ^{[8
]}

Sawada, Reimin ^{[9
]}

Oishi, Takayuki ^{[10
]}

Tsukiji, Jun ^{[11
]}

Fujita, Hiroyuki ^{[12
]}

Furuya, Ryosuke ^{[13
]}

Masuda, Makoto ^{[14
]}

Akasaka, Osamu ^{[15
]}

Ikeda, Yu ^{[15
]}

Sakamoto, Mitsuo ^{[5
]}

Sakai, Kazuya ^{[16
]}

Uchiyama, Munehito ^{[16
]}

Watanabe, Hiroki ^{[17
]}

Yamaguchi, Nobuhiro ^{[18
]}

Higa, Ryoko ^{[11
]}

Sasaki, Akiko ^{[19
]}

Tanaka, Katsuaki ^{[20
]}

Toyoda, Yukitoshi ^{[21
]}

Hamanaka, Shinsuke ^{[22
]}

Miyazawa, Naoki ^{[23
]}

Shimizu, Atsuko ^{[24
]}

Fukase, Fumie ^{[24
]}

Iwai, Shunsuke ^{[8
]}

Komase, Yuko ^{[25
]}

Kawasaki, Tsutomu ^{[26
]}

Nagata, Isao ^{[27
]}

Nakayama, Yusuke ^{[28
]}

Takei, Tetsuhiro ^{[27
]}

Kimura, Katsuo ^{[29
]}

Kunisaki, Reiko ^{[30
]}

Kudo, Makoto ^{[31
]}

Takeuchi, Ichiro ^{[32
,33
]}

Nakajima, Hideaki ^{[2
]}

机构：

[1] Yokohama City Univ Med, Infect Prevent & Control Dept, Yokohama, Kanagawa, Japan

[2] Yokohama City Univ, Dept Hematol & Clin Immunol, Sch Med, Yokohama, Kanagawa, Japan

[3] Fujisawa City Hosp, Dept Clin Lab Med, Fujisawa, Kanagawa, Japan

[4] Yokohama City Minato Red Cross Hosp, Dept Infect Dis, Yokohama, Kanagawa, Japan

[5] Kawasaki Municipal Kawasaki Hosp, Dept Infect Dis, Kawasaki, Kanagawa, Japan

[6] Kanagawa Prefectural Ashigarakami Hosp, Dept Gen Med, Matsudo, Japan

[7] Yokosuka City Hosp, Dept Surg, Yokosuka, Kanagawa, Japan

[8] St Marianna Univ, Dept Emergency & Crit Care Med, Sch Med, Yokohama City Seibu Hosp, Yokohama, Kanagawa, Japan

[9] Japanese Red Cross Hadano Hosp, Dept Cardiol, Hadano, Japan

[10] Saiseikai Yokohamashi Tobu Hosp, Dept Infect Control & Prevent, Yokohama, Kanagawa, Japan

[11] Yokohama City Univ, Dept Prevent & Infect Control, Med Ctr, Yokohama, Kanagawa, Japan

[12] Saiseikai Yokohama Nanbu Hosp, Infect Control Comm, Yokohama, Kanagawa, Japan

[13] Natl Hosp Org Yokohama Med Ctr, Dept Crit Care & Emergency Med, Yokohama, Kanagawa, Japan

[14] Fujisawa City Hosp, Dept Resp Med, Fujisawa, Kanagawa, Japan

[15] Fujisawa City Hosp, Ctr Emergency Med, Fujisawa, Kanagawa, Japan

[16] Yokohama City Univ, Dept Emergency Med, Sch Med, Yokohama, Kanagawa, Japan

[17] Yokohama City Univ, Dept Pulmonol, Grad Sch Med, Yokohama, Kanagawa, Japan

[18] Yokosuka City Hosp, Dept Resp Med, Yokosuka, Kanagawa, Japan

[19] Japanese Red Cross Hadano Hosp, Dept Nursing, Hadano, Japan

[20] Japanese Red Cross Hadano Hosp, Dept Gastroenterol, Hadano, Japan

[21] Saiseikai Yokohamashi Tobu Hosp, Dept Emergency & Crit Care Med, Major Trauma Ctr Trauma & Acute Care Surg, Yokohama, Kanagawa, Japan

[22] Saiseikai Yokohamashi Tobu Hosp, Dept Pulm Med, Yokohama, Kanagawa, Japan

[23] Saiseikai Yokohamashi Tobu Hosp, Dept Resp Med, Yokohama, Kanagawa, Japan

[24] Natl Yokohama Med Ctr, Infect Control Team, Yokohama, Kanagawa, Japan

[25] St Marianna Univ, Dept Resp Internal Med, Sch Med, Yokohama City Seibu Hosp, Yokohama, Kanagawa, Japan

[26] Yokohama City Minato Red Cross Hosp, Dept Resp Med, Yokohama, Kanagawa, Japan

[27] Yokohama City Minato Red Cross Hosp, Intens Care Unit, Yokohama, Kanagawa, Japan

[28] Yokohama City Minato Red Cross Hosp, Emergency Dept, Yokohama, Kanagawa, Japan

[29] Yokohama City Univ, Dept Neurol, Med Ctr, Yokohama, Kanagawa, Japan

[30] Yokohama City Univ, Ctr Inflammatory Bowel Dis, Med Ctr, Yokohama, Kanagawa, Japan

[31] Yokohama City Univ, Resp Dis Ctr, Med Ctr, Yokohama, Kanagawa, Japan

[32] Kanagawa Disaster Med Assistance Team, Yokohama, Kanagawa, Japan

[33] Yokohama City Univ, Adv Emergency Med Serv Ctr, Med Ctr, Yokohama, Kanagawa, Japan

来源：

JOURNAL OF INFECTION AND CHEMOTHERAPY | 2020年 / 26卷 / 08期

关键词：

Coronavirus; SARS-CoV-2; Outbreak; COVID-19; Diamond Princess cruise ship; PNEUMONIA;

D O I：

10.1016/j.jiac.2020.05.005

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We investigated the clinical course of individuals with 2019 novel coronavirus disease (COVID-19) who were transferred from the Diamond Princess cruise ship to 12 local hospitals. The conditions and clinical courses of patients with pneumonia were compared with those of patients without pneumonia. Among 70 patients (median age: 67 years) analyzed, the major symptoms were fever (64.3%), cough (54.3%), and general fatigue (24.3%). Forty-three patients (61.4%) had pneumonia. Higher body temperature, heart rate, and respiratory rate as well as higher of lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and C-reactive protein (CRP) levels and lower serum albumin level and lymphocyte count were associated with the presence of pneumonia. Ground-glass opacity was found in 97.7% of the patients with pneumonia. Patients were administered neuraminidase inhibitors (20%), lopinavir/ritonavir (32.9%), and ciclesonide inhalation (11.4%). Mechanical ventilation and veno-venous extracorporeal membrane oxygenation was performed on 14 (20%) and 2 (2.9%) patients, respectively; two patients died. The median duration of intubation was 12 days. The patients with COVID-19 transferred to local hospitals during the outbreak had severe conditions and needed close monitoring. The severity of COVID-19 depends on the presence of pneumonia. High serum LDH, AST and CRP levels and low serum albumin level and lymphocyte count were found to be predictors of pneumonia. It was challenging for local hospitals to admit and treat these patients during the outbreak of COVID-19. Assessment of severity was crucial to manage a large number of patients. (C) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

引用

页码：865 / 869

页数：5

共 13 条

[1] Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance
不详
[J]. PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2020, 16 (01): : 9 - 26
[2] [Anonymous], 2020, DIAMOND PRINCESS UPD
[3] Cruise Lines International Association, 2017, 2017 AS CRUIS REP
[4] Guan WJ, 2020, NEW ENGL J MED, V382, P1861, DOI 10.1056/NEJMc2005203
[5] Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases
Iwabuchi, Keisuke
Yoshie, Koichiro
Kurakami, Yuichi
Takahashi, Kota
Kato, Yoshio
Morishima, Tsuneo
[J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (06) : 625 - 632
[6] Nakajima Kento, 2020, Mayo Clin Proc, V95, P1296, DOI 10.1016/j.mayocp.2020.04.007
[7] National Institute of Infectious Diseases, 2020, FIELD BRIEF DIAM PRI
[8] Pan F, 2020, RADIOLOGY, DOI [10.1148/radiol.2020200370, DOI 10.1148/RADIOL.2020200370]
[9] Rockl_ov J, 2020, J TRAVEL MED, DOI [10.1093/jtm/taaa030.taaa030., DOI 10.1093/JTM/TAAA030.TAAA030]
[10] COVID-19 first stage in Japan - how we treat 'Diamond Princess Cruise Ship' with 3700 passengers?
Takeuchi, Ichiro
[J]. ACUTE MEDICINE & SURGERY, 2020, 7 (01):

← 1 2 →